Emerald Clinics (ASX:EMD) - CEO, Dr Michael Winlo
CEO, Dr Michael Winlo
Source: Business News
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Emyria (EMD) has expanded its clinical service, Emerald Clinics, with a second site in Melbourne
  • This expansion comes off the back of record patient appointments in January 2021
  • The new East Melbourne location is expected to increase patient access to Emerald Clinics as well as support trials planned for Emyria’s first drug development program, EMD-003
  • EMD-003 is the company’s first cannabinoid-based medicine, which it is aiming to have approved by the Australia’s Therapeutic Goods Administration
  • On market close for the day, Emyria is up 10.7 per cent and is trading at 15.5 cents per share

Emyria (EMD) has expanded its clinical service subsidiary, Emerald Clinics, with a second site in Melbourne.

This expansion comes off the back of record patient appointments in January 2021.

The new East Melbourne site is co-located with Victorian Counselling and Psychological Services (VCPS), a major provider of mental health services across Melbourne. VCPS is home to clinical psychologists, counsellors and psychiatrists.

The East Melbourne location is expected to increase patient access to Emerald Clinics as well as support trials planned for Emyria’s first drug development program, EMD-003.

EMD-003 is the company’s first cannabinoid-based medicine, which Emyria is aiming to have Australia’s Therapeutic Goods Administration approved.

Each Emerald Clinics site collects data with consenting patients, using a bespoke data platform.

Notably, Emyria’s data asset is one of the largest clinical-trial grade data sets in the world and helps improve care for Emerald Clinic’s patients.

“We are pleased to be able to respond to the high patient demand for our clinical care model across Australia with the addition of a new site in Melbourne,” Managing Director, Dr Michael Winlo said.

“The new site is unique in that it is co-located with Victorian Counseling and Psychological Services and offers unique collaboration opportunities with
mental health clinicians including psychologists and psychiatrists,” he added.

The second clinic will open on February 15.

On market close for the day, Emyria is up 10.7 per cent and is trading at 15.5 cents per share.

EMD by the numbers
More From The Market Online

OncoSil’s cancer device shows shrink in pancreatic tumours

OncoSil's cancer device shows shrink in pancreatic tumours at a study conducted at the Royal Adelaide…
The Market Online Video

Why Princeton Professor rates BlinkLab’s autism & ADHD screening app

In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and…

Orthocell’s Remplir shows 85% success rate in nerve repair study

Orthocell's medical device RemplirTM shows 85% success rate in latest nerve repair study, holding a promise…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.